{"id":500958,"date":"2020-08-06T18:10:01","date_gmt":"2020-08-06T18:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=500958"},"modified":"2020-08-06T18:10:01","modified_gmt":"2020-08-06T18:10:01","slug":"iga-nephropathy-igan-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/iga-nephropathy-igan-market-analysis-leading-companies-emerging-drugs-and-epidemiology-forecast_500958.html","title":{"rendered":"IgA Nephropathy (IgAN) Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast"},"content":{"rendered":"
\"IgA<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “IgA Nephropathy (IgAN) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the IgA Nephropathy (IgAN), historical and forecasted epidemiology as well as the IgA Nephropathy (IgAN) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

IgA nephropathy, also known as Berger’s disease, is a kidney disease that occurs when IgA deposits build up in the kidneys, causing inflammation that damages kidney tissues. IgA is an antibody—a protein made by the immune system to protect the body from foreign substances such as bacteria or viruses. Most people with IgA nephropathy receive care from a nephrologist, a doctor who specializes in treating people with kidney disease.<\/p>\n

IgA nephropathy usually doesn’t cause symptoms in the early stages, so the disease can go unnoticed for years or decades. It’s sometimes suspected when routine tests reveal protein and red blood cells in your urine that can’t be seen without a microscope (microscopic hematuria). In its early stages, IgA nephropathy may have no symptoms; it can be silent for years or even decades. Once symptoms appear, the most common one is hematuria, or blood in the urine. Hematuria can be a sign of damaged glomeruli. Blood in the urine may appear during or soon after a cold, sore throat, or other respiratory infection. The amount of blood may be: visible with the naked eye. The urine may turn pink or the color of tea or cola. Sometimes a person may have dark or bloody urine so small that it can only be detected using special medical tests.<\/p>\n

 <\/p>\n

Get FREE sample copy at: <\/strong>
https:\/\/www.delveinsight.com\/sample-request\/iga-nephropathy-igan-market<\/a><\/strong><\/p>\n

 <\/p>\n

 <\/p>\n

\"iga-nephropathy-igan-market-Size-and-share-analysis\"<\/p>\n

The IgA Nephropathy (IgAN) market report<\/strong> also covers emerging drugs, current treatment practices, IgA Nephropathy (IgAN) market share of the individual therapies, current and forecasted IgA Nephropathy (IgAN) Market Size from 2017 to 2030 segmented by seven major markets.<\/p>\n

The report provides a detailed current IgA Nephropathy (IgAN) treatment practice\/algorithm<\/strong>, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. <\/p>\n

 <\/p>\n

IgA Nephropathy (IgAN) Market Key Facts<\/strong><\/p>\n

IgA nephropathy is more common in males than in females. Virtually all studies show a male predominance of at least 2:1, with reported ratios of up to 6:1. The higher male predilection is observed in white patients in northern Europe and the United States.<\/p>\n

A systematic review of biopsy-based studies spanning multiple countries suggests an overall population incidence of at least 2.5 per 100,000. Only one study in this review was from Japan, and most were from Europe and North America. [Jennifer C. Rodrigues et. al., 2017]<\/p>\n

 <\/p>\n

Key Benefits of IgA Nephropathy (IgAN) Market Report<\/strong><\/p>\n